
CLAIMS

WHAT IS CLAIMED IS:

1. A compound of formula (I):



(I)

wherein:

R^1 a is targeting ligand;

L^1 is absent or a linking group;

L^2 is absent or a linking group;

R^2 is a siRNA molecule selected from any one of siRNA 1 – siRNA 119;

the ring A is absent, a 3-20 membered cycloalkyl, a 5-20 membered aryl, a 5-20 membered heteroaryl, or a 3-20 membered heterocycloalkyl;

each R^A is independently selected from the group consisting of hydrogen, hydroxy, CN, F, Cl, Br, I, -C_{1-2} alkyl-OR^B, C_{1-10} alkyl C_{2-10} alkenyl, and C_{2-10} alkynyl; wherein the C_{1-10} alkyl C_{2-10} alkenyl, and C_{2-10} alkynyl are optionally substituted with one or more groups independently selected from halo, hydroxy, and C_{1-3} alkoxy;

R^B is hydrogen or a protecting group; and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

or a salt thereof.

2. The compound of claim 1, wherein R^1 is –$C(H)_{(3-p)}(L^3$-saccharide$)_p$;


wherein each L^3 is independently a linking group;

p is 1, 2, or 3; and

saccharide is a monosaccharide or disaccharide

or a salt thereof.

3. The compound of claim 2, wherein the saccharide is:



wherein:

X is NR^3, and Y is selected from $-(C=O)R^4$, $-SO_2R^5$, and $-(C=O)NR^6R^7$; or X is -(C=O)- and Y is NR^8R^9;

R^3 is hydrogen or $(C_1\text{-}C_4)$alkyl;


R^4, R^5, R^6, R^7 , R^8 and R^9 are each independently selected from the group consisting of hydrogen, $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$haloalkyl, $(C_1\text{-}C_8)$alkoxy and $(C_3\text{-}C_6)$cycloalkyl that is optionally substituted with one or more groups independently selected from the group consisting of halo, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$alkoxy and $(C_1\text{-}C_4)$haloalkoxy;

R^{10} is -OH, $-NR^8R^9$ or – F; and

R^{11} is -OH, $-NR^8R^9$, -F or 5 membered heterocycle that is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxyl, carboxyl, amino, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$haloalkyl, $(C_1\text{-}C_4)$alkoxy and $(C_1\text{-}C_4)$haloalkoxy;


or a salt thereof.

4. The compound of claim 2 or 3, wherein the saccharide is selected from the group consisting of:



or a salt thereof.


5. The compound of any one of claims 2-4, wherein the saccharide is:





N-Acetylgalactosamine (GalNAc) GalPro

or a salt thereof.


6. The compound of claim 1, wherein the compound of formula I is selected from the group consisting of:









203, n = 3, x = 1
206, n = 4, x = 1




209, n = 3, x = 1




212, n = 3, x = 1
215, n = 4, x = 1



218, n = 2
221, n = 3



224, n = 3, x = 1




231, n = 3

and ;

and pharmaceutically acceptable salts thereof.

7. The compound of claim 1, wherein the compound of formula (I) is:



or a pharmaceutically acceptable salt thereof, wherein the siRNA depected is selected from any one of siRNA 1 – siRNA 119.

8. The compound of any one of claims 1-7, wherein the siRNA sequence comprises chemically modified nucleotides.

9. The compound of claim 8, wherein the siRNA comprises at least one 2' Ome modification or a 2'F modification.

10. The compound of claim 9, wherein the siRNA comprises at least one 2' Ome modification and at least one 2'F modification.

11. The compound of claim 9, wherein the siRNA comprises at least one 2' Ome modification and at least one 2'F modification.

12. A method of treating liver fibrosis, comprising administering to a patient in need thereof an effective amount of the compound of any one of claims 1-11.

13. A method of treating non-alcoholic steatohepatitis (NASH), comprising administering to a patient in need thereof an effective amount of the compound of any one of claims 1-11.

14. A method of treating liver fibrosis associated with non-alcoholic steatohepatitis (NASH), comprising administering to a patient in need thereof an effective amount of the compound of any one of claims 1-11.

15. A method of treating alcoholic steatohepatitis (ASH), comprising administering to a patient in need thereof an effective amount of the compound of any one of claims 1-11.

16. A method of treating liver fibrosis associated with alcoholic steatohepatitis (ASH), comprising administering to a patient in need thereof an effective amount of the compound of any one of claims 1-11.

17. The use of an effective amount of the compound of any one of claims 1-11 to treat liver fibrosis.

18. The use of an effective amount of the compound of any one of claims 1-11 to treat non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).

19. The use of an effective amount of the compound of any one of claims 1-11 to treat liver fibrosis associated non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).

20. The method or use of any one of claims 12-19, wherein the compound of formula (I) is administered subcutaneously.

21. A double stranded siRNA molecule selected from the group consisting of siRNA 1 – siRNA 119.

22. A composition comprising a double stranded siRNA molecule of claim 21.

23. An invention as described herein.